UGCG and Parkinson disease: The MOVES-PD trial is a phase II global study to assess the dynamics, efficacy, and safety of GZ/SAR402671 (Genzyme/Sanofi), a small molecule inhibitor of glucosylceramide synthase [33], in patients with early-stage PD who carry a mutation in the gene encoding glucocerebrosidase (GBA) (NCT02906020).